Thienopyridine resistance among patients undergoing intracoronary stent implantation and treated with dual antiplatelet therapy: assessment of some modifying factors

J Pharmacol Sci. 2008 Aug;107(4):451-5. doi: 10.1254/jphs.08077sc.

Abstract

In this open, prospective study we assessed the prevalence of antiplatelet resistance among patients subjected to intracoronary stent implantation. In patients treated with aspirin + thienopyridine (N = 32), platelet reactivity index (PRI) significantly decreased after 2 and 7 days of dual antiplatelet treatment in comparison with the same patients on aspirin monotherapy (P<0.001, both). After 7 days of aspirin + thienopyridine treatment, insufficient antiplatelet response was observed in 28% (9/32) of the patients. High interindividual variability in response to aspirin + thienopyridine treatment emphasizes the significance of thienopyridine resistance, while the influence of statins on such a treatment should be reassessed.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aspirin / pharmacology*
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Clopidogrel
  • Coronary Vessels / pathology
  • Coronary Vessels / surgery
  • Drug Resistance*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia / surgery
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Function Tests
  • Prospective Studies
  • Stents*
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / pharmacology
  • Time Factors

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin